Hyperglycemia in Patients With Takotsubo Syndrome

Blood Glucose Values at Hospital Admission and Clinical Outcomes in Patients With Takotsubo Syndrome: Hyperglycemia Effects on Heart Failure Events and Mortality at 24 Months of Follow-up

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04684004

Enrollment

Registered

2020-12-24

Start date

2013-01-01

Completion date

2019-01-01

Last updated

2020-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takotsubo Cardiomyopathy

Brief summary

Patients with Takotsubo cardiomiopathy (TTC) have over-inflammation and over-sympathetic tone. However, these conditions could cause higher rate of heart failure (HF) events and deaths at 2 years of follow-up. Conversely, hyperglycemia vs. normoglycemia could result in over expression of inflammatory markers and catecholamines thta could result in higher rate of HF and deaths at 2 years of follow-up in TTC patients.

Interventions

OTHERTo report number of HF events and deaths

In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* acute onset of a cardiovascular event, usually associated with substernal chest pain, initially regarded as STEMI/evolving coronary syndrome; * cardiac biomarker modifications (creatine kinase-MB and troponin I); * systolic dysfunction, predominantly characterized by akinesia/hypokinesia of the mid-to-distal portion of the left ventricle (LV) chamber, with hyper-contractile basal LV.

Exclusion criteria

* patients with previous previous myocardial infarction; * patients with previous TTC event; * patients affected by chronic kidney, liver, and cerebrovascular diseases.

Design outcomes

Primary

Measure	Time frame	Description
The number of HF events	12 months	To evaluate the number of HF events by clinical visits, telephonic interviews and hospital discharge schedules.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026